Testosterone replacement therapy was once shrouded in mystery, but recent medical breakthroughs are increasingly highlighting it as a safe and viable medical treatment for men with testosterone deficiencies.
Male hypogonadism, a deficiency in the primary male sex hormone, testosterone, affects up to 38% of men around the world, and this number is expected to grow as populations in developed countries age. Since its introduction in 1930, testosterone replacement therapy (TRT) has become one of the most commonly prescribed hormone therapies for managing this condition, though concerns over potential side effects remain to this day.
However, experts like TRT Australia have highlighted medical breakthroughs that have solidified the viability of the treatment, including the 2023 TRAVERSE trial that eventually resulted in the removal of FDA black box warnings in early 2025.
According to a literature review in Trends in Urology & Men’s Health, male hypogonadism can be a potentially serious medical condition that can have long-term implications on a man’s health. The condition becomes more prevalent with age, occurring in 20% of men over 60 years old and 30% of men over the age of 70, but it can also affect younger men, particularly those who have suffered injury to their head or testicles, are taking certain pain medications or illegal drugs, or have chronic conditions such as thyroid issues, diabetes, or obesity.
Because testosterone is required for muscle development, experts say that low testosterone levels can result in muscle and bone loss and increases in visceral fat despite regular exercise; if left untreated over the long term, the condition can contribute to the development of issues such as male osteoporosis and sarcopenia.
In addition, low testosterone is known to cause other symptoms that can reduce quality of life, including persistent fatigue, mood changes, and brain fog.
However, health experts say that testosterone replacement therapy (TRT) is a viable treatment that can be used to address testosterone deficiencies and reverse the aforementioned symptoms as long as it is medically appropriate.
While there have been numerous concerns about how TRT impacts an individual’s risks of developing cardiovascular disease or cancer, results from the 2023 TRAVERSE suggested that men undergoing treatment were no more at risk than those who were not. Following rigorous reviews initiated by the FDA, black box warnings for TRT were removed in early 2025, marking a change in the risk-benefit framework for the treatment.
Modern testosterone therapy also incorporates advances that align with contemporary clinical standards, ensuring that patients who receive treatment from licensed physicians will remain safe.
There are several modes of testosterone delivery in typical TRT treatments, but common ones include injectable medications, topical applications, transdermal patches, and oral medications.
Experts note that injections are the fastest-acting, but they may be accompanied by side effects such as injection site reactions and increased red blood cell count.
Transdermal patches and topical treatments may be preferred by some patients because they are less invasive, but they must be applied according to guidelines from healthcare providers to ensure maximum absorption.
Finally, oral testosterone medications are another possible mode of delivery, but they are often not recommended as the first line of treatment, as they can result in hormone fluctuations and impact liver function.
Most men on TRT report health benefits such as enhanced mental clarity, better moods, increased energy, and improved muscle mass.
In spite of rigorous research, there remain a number of contraindications for TRT. As a result, patients must still undergo diagnostic blood work and consult a healthcare professional before they commit to treatment to determine whether it is medically appropriate.
